🎯Today's Pharma Pulse
Updated 1h agoWhat's happening: Merck and Pfizer’s Keytruda‑Padcev combo reshapes bladder cancer treatment
In the Phase 3 EV‑304 trial, the Merck‑Pfizer doublet cut the risk of disease progression, recurrence or death by 47% compared with gemcitabine‑cisplatin and lowered overall‑mortality risk by 35%. Pathological complete response increased to 55.8% versus 32.5% in the control arm, signaling a potential new standard of care for muscle‑invasive bladder cancer.
Also developing:
News•Feb 19, 2026
MSD and Mayo Clinic Team up to Advance AI in Drug Development
Merck & Co (MSD) and Mayo Clinic have launched a research partnership that leverages AI, advanced analytics, and multimodal clinical‑genomic data to accelerate drug discovery and precision medicine. The collaboration merges Mayo’s Platform architecture and de‑identified datasets—including imaging, labs, molecular data, and clinical notes—with MSD’s virtual cell technologies to improve target identification and early development decisions. Initial efforts will focus on therapies for atopic dermatitis, multiple sclerosis, and inflammatory bowel disease. The deal also grants MSD direct access to Mayo’s biorepositories and AI tools through the Platform Orchestrate programme.
By Pharmaceutical Technology (GlobalData)
News•Feb 19, 2026
Opinion: My Biggest GLP-1 Ethical Problem: Patients Who Don’t Want to Stop
GLP‑1 agonists have moved from scarcity to abundance, reshaping weight‑management practice. In 2023, shortages forced clinicians to ration these drugs, often off‑label for obesity. Today, the surplus creates a new dilemma: patients seeking extreme, unsustainable weight loss and refusing to...
By STAT News — Pharma
Blog•Feb 19, 2026
UV Red Flag: Color-Changing ‘Living’ Material Warns of Harmful Radiation
Researchers at the Technical University of Munich have created a bio‑hybrid coating that visibly signals UV‑A exposure by turning from green to red. The sensor embeds dry Escherichia coli cells loaded with the photoconvertible protein mEosFP, which undergoes an irreversible...
By BioTechniques (independent journal site)
Blog•Feb 18, 2026
Genentech’s Fenebrutinib Yields Positive Results in Phase III MS Trial
Genentech’s oral BTK inhibitor fenebrutinib met its primary endpoint in the Phase III FENtrepid trial for primary progressive multiple sclerosis, showing non‑inferiority to Ocrevus and a 12% risk reduction in confirmed disability progression. The drug also delivered a 26% lower risk...
By Xtalks – Biotech Blogs
News•Feb 18, 2026
STAT+: New FDA Guidance for Antibiotic Use in Food-Producing Animals Prompts Criticism over Antibiotic Resistance
The FDA’s Center for Veterinary Medicine issued new guidance urging drugmakers to add explicit duration limits to medically important antibiotics used in food‑producing animals. Currently, about 28% of these drugs are administered continuously for approved indications, but the guidance seeks...
By STAT News — Pharma
Blog•Feb 18, 2026
Anti-Aging Gene Therapy in Alzheimer’s and ALS with Klotho Neurosciences’ Dr. Joseph Sinkule — Episode 243
The Xtalks Life Science Podcast featured Joseph Sinkule, CEO of Klotho Neurosciences, discussing the company’s secreted α‑Klotho gene therapy platform aimed at age‑related neurodegenerative diseases such as Alzheimer’s, ALS and Parkinson’s. Klotho leverages a patented anti‑aging gene to develop cell‑ and...
By Xtalks – Biotech Blogs
News•Feb 18, 2026
FDA to Review Moderna’s Flu Jab on Agency Pivot
The FDA has reversed its earlier refusal and will now evaluate Moderna’s mRNA‑1010 seasonal flu vaccine using a two‑track approach: a full Biologics License Application review for adults 50‑64 and an accelerated approval pathway for those 65 and older, contingent...
By Pharmaceutical Technology (GlobalData)
Blog•Feb 18, 2026
Global Conference to Tackle Longevity Clinical Translation
The National University of Singapore Academy for Healthy Longevity is hosting the Geromedicine Conference on February 26-27, 2026, bringing together geroscience researchers, clinicians, and industry leaders. The event emphasizes clinical translation of molecules such as NAD+ precursors, urolithin A, and ergothioneine,...
By SENS Research Foundation – The SENSible Blog
Blog•Feb 18, 2026
How Does Cholera Colonize the Gut? Unmasking Virulence Activation with Cryo-EM
Cryogenic electron microscopy enabled researchers to solve five structures of Vibrio cholerae transcription activation complexes, revealing how the bacterium initiates virulence in the human gut. The study shows ToxR and TcpP transcription factors bind the RNA polymerase α‑C‑terminal domain via...
By BioTechniques (independent journal site)
Blog•Feb 18, 2026
Patent Cliff Pressures to Drive Big Pharma M&A
The looming patent cliff, projected to strip up to $300 billion in annual drug sales by 2032, is keeping large pharma firms focused on strategic acquisitions rather than triggering a sudden surge in deal volume. Dan Chancellor of Norstella notes that...
By Pharmaceutical Commerce (independent trade)
Blog•Feb 18, 2026
Global Genomics: Representative Research Is Key to Unlocking the Full Potential of Precision Medicine
Professor Segun Fatumo highlights the stark under‑representation of African genomes in global research, where over 86% of GWAS participants are of European ancestry despite Africa housing the greatest genetic diversity. He explains how this gap limits the accuracy of polygenic...
By BioTechniques (independent journal site)
Blog•Feb 18, 2026
The Biotech Bi-Weekly: A 48-Channel SPR Platform, Robust RNA-Seq Libraries and Microgravitational Discoveries
Carterra unveiled Vega, the industry’s first 48‑channel high‑throughput SPR platform, delivering roughly 12‑fold higher screening capacity for small‑ and large‑molecule drug candidates. Covaris introduced the truCOVER® Total RNA Library Prep Kit, enabling robust RNA‑seq libraries from as little as 10 ng...
By BioTechniques (independent journal site)
News•Feb 18, 2026
Opinion: I Was a Moderna Exec when the Covid Vaccine Rolled Out. That Spirit of Possibility Is No More
Former Moderna executive Richard Hughes IV reflects on the exhilaration of the COVID‑19 vaccine launch, describing a once‑vibrant "spirit of possibility" that drove rapid innovation. He recounts his personal journey from unknown outsider to key player in a global health...
By STAT News — Pharma
News•Feb 17, 2026
STAT+: At Drugmakers’ Forum, Oz Gets a Friendly Embrace, While Makary Faces Tough Questions
At a PhRMA‑hosted forum, CMS Administrator Mehmet Oz engaged warmly with Pfizer CEO Albert Bourla, championing vaccines and proposing closed‑door policy talks and even suggesting industry executives consider government jobs. In contrast, FDA Commissioner Marty Makary was sharply questioned by...
By STAT News — Pharma
Blog•Feb 17, 2026
Free Access to Single-Cell Long-Read mRNA Sequencing Tech with New Grant
ArgenTag, now a PacBio Compatible Partner, has launched a grant that provides free access to its Single‑Cell RNA Library Kit for Long‑Read Sequencing. The kit uses a gravity‑based microfluidic chip to isolate individual cells, capture full‑length mRNA, and prepare barcoded...
By BioTechniques (independent journal site)
Podcast•Feb 17, 2026•16 min
DDW Highlights: 17 February 2026
In this 16‑minute DDW Highlights episode, host Bruno Quinney recaps five major drug‑discovery stories from the past week, focusing on a breakthrough study linking specific biomarkers to improved cancer survival rates and the launch of a multinational consortium tackling chronic...
By The Drug Discovery World Podcast
Blog•Feb 17, 2026
Rare Disease Month Developments, Part 1 – The Good: RPD PRV Program Renewed, FDA Rare Disease Hub’s 2026 Strategic Agenda...
Congress renewed the Rare Pediatric Disease Priority Review Voucher (RPD PRV) program, extending it to September 30 2029 and eliminating the dual sunset dates. The FDA released its Rare Disease Innovation Hub’s 2026 Strategic Agenda, allocating $1 million in funding and outlining plans...
By FDA Law Blog
Blog•Feb 16, 2026
Silencing Growth Hormone Has Strong Effects in Mouse Brains
Researchers engineered mice lacking growth hormone receptors specifically in adipose tissue (Ad‑GHRKO) and observed striking brain benefits in aged males. Compared with control mice, the Ad‑GHRKO group showed increased neuronal activity, reduced neuroinflammation, lower tau phosphorylation, and fewer senescence markers....
By SENS Research Foundation – The SENSible Blog
Blog•Feb 16, 2026
Who Qualifies for the New FDA PreCheck Pilot Program?
The FDA has opened submissions for its PreCheck Pilot Program, targeting new U.S. drug‑manufacturing facilities that will begin construction by the March 1 2026 deadline. Eligible sites must be stand‑alone plants, located in the United States or its territories, and commit to...
By FDA Law Blog
Podcast•Feb 15, 2026•0 min
🎧 The GLP-1 Business Model Problem, Ep. 1 with Prof. Alex Miras
In the inaugural episode, host Alex discusses the GLP‑1 business model with obesity expert Prof. Alex Miras, who emphasizes that the drug itself drives the bulk of weight loss—about 20% versus 2.5% from behavioral support—making extensive multidisciplinary care unnecessary for...
By GLP-1 Digest
Blog•Feb 13, 2026
Longevity Innovation Forum in San Diego
Longevity Global is launching the inaugural Longevity Innovation Forum in San Diego on March 11‑12, 2026, gathering leading scientists, clinicians, biotech founders and investors to accelerate healthy‑aging research. The two‑day summit features high‑profile speakers such as Mike Snyder, Eric Verdin,...
By SENS Research Foundation – The SENSible Blog
Blog•Feb 13, 2026
Cellular Reprogramming Rescues Memory-Encoding Neurons
Scientists at EPFL applied a three‑factor (OSK) partial reprogramming cocktail to memory‑encoding engram neurons in 9‑10‑month‑old mice and Alzheimer’s‑model strains. Using a dual‑AAV system gated by doxycycline, OSK expression was limited to neurons active during a learning event, preserving cell...
By SENS Research Foundation – The SENSible Blog
Blog•Feb 12, 2026
Creating CAR-T Cells Using Current Alzheimer’s Antibodies
Researchers engineered CD4+ T cells with chimeric antigen receptors (CARs) derived from FDA‑approved Alzheimer’s antibodies aducanumab and lecanemab. The lecanemab‑based CAR (Lec28z) selectively bound fibrillar amyloid‑beta and reduced plaque burden in mouse brains, especially when delivered via transient mRNA transfection....
By SENS Research Foundation – The SENSible Blog
Blog•Feb 12, 2026
Can a Citizen Petition Denial Turn a Warning Letter Into Final Agency Action? The Curious Case of Hybrid Pharma
The Southern District of Florida held that a denial of a citizen petition transforms the underlying FDA warning letters into final agency action, allowing judicial review. Hybrid Pharma sued after the FDA refused to rescind two warning letters and the...
By FDA Law Blog
Blog•Feb 11, 2026
Young Microbes Rejuvenate Intestinal Function in Mice
Researchers performed heterochronic fecal microbiota transplants, moving gut microbes from young to aged mice, which reactivated canonical Wnt signaling and enhanced intestinal stem cell regeneration. Aged mice receiving young microbiota showed increased expression of Wnt3, Ascl2, Lgr5 and improved epithelial...
By SENS Research Foundation – The SENSible Blog
Blog•Feb 11, 2026
ACI’s 22nd Annual Paragraph IV Disputes: Elevate Your 2026 Hatch-Waxman Strategy
The American Conference Institute will host its 22nd Annual Paragraph IV Disputes Conference on April 21‑22, 2026 in New York’s Times Center. The two‑day forum gathers brand‑name and generic drug stakeholders to discuss Hatch‑Waxman litigation strategies, recent case law, and evolving PTAB practices. Featured...
By FDA Law Blog
Podcast•Feb 10, 2026•15 min
DDW Highlights: 10 February 2026
In this 15‑minute episode, DDW host Bruno Quinney recaps five major stories from the past week, highlighting breakthrough cancer therapies that promise greater efficacy and safety, and new research aimed at enhancing brain function in Alzheimer’s patients. He also touches...
By The Drug Discovery World Podcast
Blog•Feb 9, 2026
Sixth Circuit Affirms Steep Sentence in FDC Act Counterfeiting Case
The Sixth Circuit Court of Appeals affirmed a 90‑month prison term for Omar Wala, who pleaded guilty to conspiring to manufacture and distribute counterfeit generic alprazolam pills on the dark web. The court upheld the district court’s fraud loss calculation,...
By FDA Law Blog